Compare Eos Energy Enterprises Inc (EOSE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eos Energy Enterprises Inc vs Pfizer Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.81 (market cap $1.13B), while Pfizer Inc trades at $27.77 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 141.2× Eos Energy Enterprises Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Pfizer Inc for 158 Days on average.
| EOSE | PFE | |
|---|---|---|
Market Cap | $1.13B | $159.59B |
Volume | 17,918,777 | 30,937,010 |
Sector | Industrials | Health |
52-Week High | $19.19 | $29.02 |
52-Week Low | $2.77 | $23.67 |
Typical Hold Time | 16 Days | 158 Days |
Enterprise Value | $1.47B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% on the day, with a bearish technical signal from moving averages. The company is in a high-growth phase, with revenue surging from $114.20 million in 2025 to $214 million in 2026, though it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.
The outlook is a mix of high growth potential and significant financial risk. Analyst consensus is a 'Buy' with a $7.10 price target, implying substantial upside, but the stock carries execution risk as the company burns cash to scale. Investors are betting on EOSE capturing market share in long-duration energy storage, but must tolerate volatility and ongoing losses.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eos Energy Enterprises Inc
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
